Prophylactic activity of intramuscular peramivir in mice infected with a recombinant influenza A/WSN/33 (H1N1) virus containing the H274Y neuraminidase mutation

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 7, 2010, Pages 2819-2822

  Abed, Yacine ^a   Simon, Philippe ^a   Boivin, Guy ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

OSELTAMIVIR; PERAMIVIR; SIALIDASE; ANTIVIRUS AGENT; CYCLOPENTANE DERIVATIVE; GUANIDINE DERIVATIVE; VIRUS PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; FATALITY; GENE MUTATION; IC 50; INFLUENZA; INFLUENZA VIRUS A H1N1; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; WEIGHT REDUCTION; ANIMAL; BAGG ALBINO MOUSE; CELL LINE; DOG; ENZYMOLOGY; GENETICS; INTRAMUSCULAR DRUG ADMINISTRATION; MUTATION; ORTHOMYXOVIRIDAE INFECTIONS;

ANIMALS; ANTIVIRAL AGENTS; CELL LINE; CYCLOPENTANES; DOGS; GUANIDINES; INFLUENZA A VIRUS, H1N1 SUBTYPE; INJECTIONS, INTRAMUSCULAR; MALE; MICE; MICE, INBRED BALB C; MUTATION; NEURAMINIDASE; ORTHOMYXOVIRIDAE INFECTIONS; VIRAL PROTEINS;

EID: 77953754728     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01681-09     Document Type: Article

References (18)

1. Abed, Y., N. Goyette, and G. Boivin. 2004. A reverse genetics study of resistance to neuraminidase inhibitors in an influenza A/H1N1 virus. Antivir. Ther. 9:577-581.
2. Abed, Y., and G. Boivin. 2006. Treatment of respiratory virus infections. Antiviral Res. 70:1-16.
3. Aoki, F. Y., G. Boivin, and N. Roberts. 2007. Influenza virus susceptibility and resistance to oseltamivir. Antivir. Ther. 12:603-616.
4. Babu, Y. S., P. Chand, S. Bantia, P. Kotian, A. Dehghani, Y. El-Kattan, T. H. Lin, T. L. Hutchison, A. J. Elliott, C. D. Parker, S. L. Ananth, L. L. Horn, G. W. Laver, and J. A. Montgomery. 2000. BCX-1812 (RWJ-270201): discovery of a novel, highly potent, orally active, and selective influenza neuraminidase inhibitor through structure-based drug design. J. Med. Chem. 43:3482-3486.
5. Bantia, S., C. S. Arnold, C. D. Parker, R. Upshaw, and P. Chand. 2006. Anti-influenza virus activity of peramivir in mice with single intramuscular injection. Antiviral Res. 69:39-45.
6. Barroso, L., J. Treanor, L. Gubareva, and F. G. Hayden. 2005. Efficacy and tolerability of the oral neuraminidase inhibitor peramivir in experimental human influenza: randomized, controlled trials for prophylaxis and treatment. Antivir. Ther. 10:901-910.
7. Baz, M., Y. Abed, B. Nehmé, and G. Boivin. 2009. Activity of the oral neuraminidase inhibitor A-322278 against the oseltamivir-resistant H274Y (A/H1N1) influenza virus mutant in mice. Antimicrob. Agents Chemother. 53:791-793.
8. Baz, M., Y. Abed, J. Papenburg, X. Bouhy, M. E. Hamelin, and G. Boivin. 2009. Emergence of oseltamivir-resistant pandemic H1N1 virus during prophylaxis. N. Engl. J. Med. 23:2296-2297.
9. Baz, M., Y. Abed, P. Simon, M. E. Hamelin, and G. Boivin. 2010. Impact of the neuraminidase mutation H274Y conferring resistance to oseltamivir on the replicative capacity and virulence of different influenza A/H1N1 viruses. J. Infect. Dis. 201:740-745.
10. Boivin, G., and N. Goyette. 2002. Susceptibility of recent Canadian influenza A and B virus isolates to different neuraminidase inhibitors. Antiviral Res. 54:143-147.
11. Bright, R. A., D. K. Shay, B. Shun, N. J. Cox, and A. L. Klimov. 2006. Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States. JAMA 295:891-894.
12. de Jong, M. D., T. T. Tran, H. K. Truong, M. H. Vo, G. J. Smith, V. C. Nguyen, T. Q. Phan, Q. H. Do, Y. Guan, J. S. Peiris, T. H. Tran, and J. Farrar. 2005. Oseltamivir resistance during treatment of influenza A(H5N1) infection. N. Engl. J. Med. 353:2667-2672.
13. Dharan, N. J., L. V. Gubareva, and J. J. Meyer. 2009. Infections with oseltamivir resistant influenza A/H1N1 virus in the United States. JAMA 301:1034-1041.
14. Gubareva, L. V., R. G. Webster, and F. G. Hayden. 2001. Comparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants. Antimicrob. Agents Chemother. 45:3403-3408.
15. Hurt, A. C., J. Ernest, Y. M. Deng, P. Lanello, T. G. Besselaer, C. Birch, P. Buchy, M. Chittaganpitch, S. C. Chiu, D. Dwyner, A. Guigon, B. Harrower, L. P. Kei, T. Kok, C. Lin, K. McPhie, A. Mohd, R. Olveda, T. Panayotou, W. Rawlinson, L. Scott, D. Smith, H. D'Souza, N. Komadina, R. Shaw, A. Kelso, and I. G. Barr. 2009. Emergence and spread of oseltamivir-resistant A(H1N1) influenza viruses in Oceania, South East Asia and South Africa. Antiviral Res. 83:90-93.
16. Moscona, A. 2005. Neuraminidase inhibitors for influenza. N. Engl. J. Med. 353:1363-1373.
17. Sidwell, R. W., D. F. Smee, J. H. Hufman, D. L. Barnard, K. W. Bailey, J. D. Morrey, and Y. S. Babu. 2001. In vivo influenza virus-inhibitory effects of the cyclopentane neuraminidase inhibitor RWJ-270201. Antimicrob. Agents Chemother. 45:749-757.
18. Yoshida, R., M. Kodama, M. Kobayashi, M. Kitano, A. Sato, and Y. Yamano. 2009. Therapeutic effect of peramivir (S-021812, BCX-1812) after single intravenous treatment of mice infected with influenza A and B viruses, abstr. V-1065, p. 67. Abstr. 49th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.